Deals, Chips, and a Turnaround Under Pressure
Two deals dominated early headlines. ABBV is closing in on an ~$11 billion acquisition of biotech APGE. Options markets flagged this Friday — APGE carries 18.1% short interest, making a squeeze likely at deal close.…